What Researchers Did
Clinicians in India studied 38 patients who developed a dangerous fungal infection called mucormycosis after COVID-19, treating them with surgery plus a combination of antifungal medication, HBOT, and methylene blue.
What They Found
After surgery and the three-part adjunctive treatment, none of the 38 patients experienced further spread of the infection over a two-year follow-up period. The most common side effects were wound separation (39.5%) and pus discharge (5.3%). Only 5.3% experienced temporary hearing changes during HBOT, which resolved after treatment.
What This Means for Canadian Patients
COVID-19-associated mucormycosis was a serious complication during the pandemic, particularly for diabetic patients on steroids. This study suggests that HBOT, as part of a combined treatment plan, can stop disease progression even in severe cases involving the jaw and sinuses.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a small retrospective observational study without a control group, so it is not possible to determine how much each individual treatment contributed to the outcomes.